NKTR beat EPS expectations by 16.32%
Nov 07, 2024, 11:32 PM
0.00%
What does NKTR do
Nektar Therapeutics, a San Francisco-based biopharmaceutical company with 137 employees, focuses on developing immunotherapy medicines for oncology and immunology, including NKTR-255 and Rezpegaldesleukin. Its pipeline targets immune response pathways to address cancer and autoimmune conditions.
Nektar Therapeutics (NKTR) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Nektar Therapeutics's actual EPS was -$0.18, beating the estimate of -$0.22 per share, resulting in a 16.32% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.